Status:
UNKNOWN
Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection
Lead Sponsor:
Tampere University Hospital
Conditions:
COVID-19
SARS-CoV-2 Infection
Eligibility:
All Genders
18-70 years
Brief Summary
A Study of the relation of COVID-19 infection and its severity to upper and lower airway nitric oxide, upper airway viral load and lung function.
Detailed Description
Materials and methods: Prospective cohort of 40 COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), positive patients from Tampere university hospital region are recruited to the s...
Eligibility Criteria
Inclusion
- capable of breathing through nose, no need of supplemental oxygen, symptom onset within 10 days, positive SARS-CoV-2 test in Fimlab and capable of performing all required tests
Exclusion
- need of supplemental oxygen, pregnancy, lactation, incapability of performing the tests for any reason, use of organic nitrate medication
Key Trial Info
Start Date :
January 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 15 2024
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT04728919
Start Date
January 15 2021
End Date
January 15 2024
Last Update
February 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tampere University Hospital
Tampere, Finland